Stroke-Like Migraine Attacks After Radiation Therapy Syndrome
Neurol 104:e210203, Lubotzky,A.,t al, 2025
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Clinicopathologic Conference, MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke like episodes)
NEJM 376:1668-1678, CASE 13-2017, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Stroke and NonStroke Brain Attacks in Children
Neurol 82:1434-1440, Mackay, M.T.,et al, 2014
Young Patient with Headache and Amaurosis Fugax
Stroke 45:e3-e4, Saarela, M.,et al, 2013
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Oxcarbazepine in Migraine Headache: A Double-Blind, Randomized, Placebo-Controlled Study
Neurol 70:548-555, Silberstein,S.,et al, 2008
Sumatriptan-Naproxen for Acute Treatment of Migraine, A Randomized Trial
JAMA 297:1443-1454, Brandes,J.L.,et al, 2007
Migraine With Unilateral Motor Symptoms: A Case-Control Study
JNNP 78:600-604,553, Young,W.B.,et al, 2007
Randomized Trial of IV Dexamethasone for Acute Migraine in the Emergency Department
Neurol 69:2038-2044, Friedmna,B.W.,et al, 2007
Metabolic Disease and Stroke: MELAS
emedicine.com, Mandava,P.,et al, 2006
Episodic Neurologic Dysfunction with Migraine and Reversible Imaging Findings After RadiationRRH
Neurol 67:676-678, Pruitt,A.,et al, 2006
A Randomized Trial of Rizatriptan in Migraine Attacks in Children
Neurol 67:1135-1140, Ahonen,K.,et al, 2006
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Acupuncture for Patients with Migraine
JAMA 293:2118-2125, Linde,K.,et al, 2005
Intermittent Headaches as the Presenting Sign of Subacute Angle-Closure Glaucoma
Neurol 65:757-758, Shindler,K.S.,et al, 2005
Acute Confusional Migraine
Int J Ch Neuropsychiatry 2:189-194, Gascon, G.G.,et al, 2005
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
"CADASIL Coma"" An Underdiagnosed Acute Encephalopathy
JNNP 74:249-252, Schon,F.,et al, 2003
Malpractice Claims: Outcome Evidence to Guide Neurologic Education?
Neurol 56:1099-1100,991, Glick,T.H., 2001
Stroke in a Healthy 46-Year-Old Man
JAMA 285:2757-2762, Wityk,R.J., 2001